Viewing nowCombinationSebiruca Tablet 10/40mg (Amlodipine, Olmesartan)
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202003822 · Approved 2020.05.26 · Insurance code 694004480
Treatment of essential hypertension not controlled with monotherapy
This medication is used in patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with Amlodipine or Olmesartan Medoxomil. Maintaining blood pressure within the normal range is crucial in essential hypertension, and this drug helps effectively lower blood pressure, aiding in the prevention of complications. Therefore, this medication is suitable for individuals who have difficulties managing their blood pressure and is used to improve blood pressure.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medication. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2, “Patients who should not receive this medication,” under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Children: The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any of the components of this medication, those who are pregnant or breastfeeding, those with severely impaired liver or kidney function, and those with specific heart conditions should not take this medication. In patients with depleted body fluids or salts, hypotension symptoms may occur, so careful monitoring of their condition should be performed especially during the early stages of treatment. There is a possibility of a sharp drop in blood pressure due to rapid vascular dilation, and if such symptoms occur, healthcare professionals should be notified immediately. Patients with weak heart or kidney function require careful observation and management when taking this medication. Adverse effects such as dizziness, headaches, low blood pressure, digestive disturbances, and skin rashes may occur during the use of this medication. If symptoms are severe or persistent, consultation with a physician is advised. This medication can interact with other drugs, so it is essential to inform healthcare professionals of any currently taken medications. In particular, taking this medication with grapefruit juice may lead to an unexpectedly strong blood pressure lowering effect, so it is advisable to avoid it. Women who are pregnant or planning to become pregnant should choose other treatment methods that are safe for the fetus instead of this medication, and immediately discontinue its use upon confirmation of pregnancy. While breastfeeding, this medication may pass into breast milk and affect the baby, so it is recommended to either stop breastfeeding or discontinue this medication. Children under 18 years of age should not take this medication as its safety and efficacy have not been established. Elderly patients may experience different effects and side effects due to impaired kidney and liver function, so it is advisable to start with a lower dose and be cautious in monitoring.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained at room temperature between 1 degree and 30 degrees.
Reddish-brown round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.